A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

March 30, 2028

Study Completion Date

April 30, 2030

Conditions
Non-small Cell Lung CancerLung Cancer
Interventions
DRUG

valemetostat tosylate

Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.

DRUG

pembrolizumab

One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.

Trial Locations (45)

1199

RECRUITING

Hospital Italiano de Buenos Aires, Buenos Aires

1426

RECRUITING

Instituto Alexander Fleming, Buenos Aires

2000

NOT_YET_RECRUITING

Instituto Medico de La Fundacion Estudios Clinicos, Rosario

4600

NOT_YET_RECRUITING

Fundacion Ars Medica, N Salvador de Jujuy

10032

NOT_YET_RECRUITING

Columbia University Irving Medical Center, New York

10461

RECRUITING

Montefiore Medical Center, The Bronx

16247

NOT_YET_RECRUITING

The Catholic University of Korea, St. Vincent'S Hospital, Suwon

19107

RECRUITING

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

22031

RECRUITING

Virginia Cancer Specialist, Fairfax

32224

NOT_YET_RECRUITING

Mayo Clinic Hospital, Jacksonville

40536

RECRUITING

University of Kentucky Medical Center, Lexington

41501

RECRUITING

Pikeville Medical Center, Pikeville

55904

NOT_YET_RECRUITING

Mayo Clinic - Rochester, Rochester

90027

RECRUITING

California Research Institute, Los Angeles

90067

RECRUITING

Valkyrie Clinical Trials, Los Angeles

92037

RECRUITING

University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla

110001

NOT_YET_RECRUITING

The First Hospital of China Medical University, Shenyang

130000

RECRUITING

Jilin Cancer Hospital, Changchun

130021

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

154007

RECRUITING

Jiamusi Cancer Hospital, Jiamusi

200120

RECRUITING

Shanghai East Hospital, Shanghai

242332

RECRUITING

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tiyuan

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

611730

NOT_YET_RECRUITING

Chengdu Shang Jin Nan Fu Hospital, Chengdu

33322-5426

RECRUITING

BRCR Global, Plantation

X5000JHQ

NOT_YET_RECRUITING

Sanatorio Allende, Córdoba

B2700CPM

NOT_YET_RECRUITING

Centro de Investigacion Pergamino Sa, Pergamino

R8500ACE

RECRUITING

Clinica Viedma S.A., Viedma

89010-340

RECRUITING

Centro de Pesquisas Clinica Reichow, Blumenau

88301-220

NOT_YET_RECRUITING

Clínica de Neoplasias Litoral Ltda., ItajaĂ-

69005-080

RECRUITING

CINPAM Centro Integrado De Pesquisa Da Amazonia, Manaus

59062-000

RECRUITING

Liga Norte-Rio-Grandense Contra o Câncer, Natal

91350-280

RECRUITING

Hospital Nossa Senhora da Conceicao, Porto Alegre

09060-650

NOT_YET_RECRUITING

Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia, Santo André

15090-000

RECRUITING

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, Sao Jose Rio Preto

812-8582

RECRUITING

Kyushu University Hospital, Fukuoka

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

135-8550

RECRUITING

Cancer Institute Hospital of JFCR, Kōtoku

460-0001

RECRUITING

NHO Nagoya Medical Center, Nagoya

252-0375

RECRUITING

Kitasato University Hospital, Sagamihara-shi

03722

NOT_YET_RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

06351

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

110-744

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY

NCT06644768 - A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Biotech Hunter | Biotech Hunter